Literature DB >> 19139100

Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.

Zehra Pamuklar1, Lorenzo Federico, Shuying Liu, Makiko Umezu-Goto, Anping Dong, Manikandan Panchatcharam, Zachary Fulkerson, Zachary Fulerson, Evgeny Berdyshev, Viswanathan Natarajan, Xianjun Fang, Laurens A van Meeteren, Wouter H Moolenaar, Gordon B Mills, Andrew J Morris, Susan S Smyth.   

Abstract

The lipid mediator lysophosphatidic acid (LPA) is a potent regulator of vascular cell function in vitro, but its physiologic role in the cardiovasculature is largely unexplored. To address the role of LPA in regulating platelet function and thrombosis, we investigated the effects of LPA on isolated murine platelets. Although LPA activates platelets from the majority of human donors, we found that treatment of isolated murine platelets with physiologic concentrations of LPA attenuated agonist-induced aggregation. Transgenic overexpression of autotaxin/lysophospholipase D (Enpp2), the enzyme necessary for production of the bulk of biologically active LPA in plasma, elevated circulating LPA levels and induced a bleeding diathesis and attenuation of thrombosis in mice. Intravascular administration of exogenous LPA recapitulated the prolonged bleeding time observed in Enpp2-Tg mice. Enpp2+/- mice, which have approximately 50% normal plasma LPA levels, were more prone to thrombosis. Plasma autotaxin associated with platelets during aggregation and concentrated in arterial thrombus, and activated but not resting platelets bound recombinant autotaxin/lysoPLD in an integrin-dependent manner. These results identify a novel pathway in which LPA production by autotaxin/lysoPLD regulates murine hemostasis and thrombosis and suggest that binding of autotaxin/lysoPLD to activated platelets may provide a mechanism to localize LPA production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139100      PMCID: PMC2652269          DOI: 10.1074/jbc.M807820200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Structure and function of murine alphaIIbbeta3 (GPIIb/IIIa): studies using monoclonal antibodies and beta3-null mice,.

Authors:  S S Smyth; D A Tsakiris; L E Scudder; B S Coller
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Platelet aggregation and increased pulmonary vascular resistance in cats induced by DAS and ADP.

Authors:  K A Schumacher; H G Classen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

3.  Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia.

Authors:  Betty A Maddux; Yow-Ning Chang; Domenico Accili; Owen P McGuinness; Jack F Youngren; Ira D Goldfine
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11-08       Impact factor: 4.310

Review 4.  International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Edward J Goetzl; Timothy Hla; Yasuyuki Igarashi; Kevin R Lynch; Wouter Moolenaar; Susan Pyne; Gabor Tigyi
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

5.  Characterisation of species differences in the platelet ADP and thrombin response.

Authors:  Sven Nylander; Christer Mattsson; Tomas L Lindahl
Journal:  Thromb Res       Date:  2006       Impact factor: 3.944

6.  Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.

Authors:  Laurens A van Meeteren; Paula Ruurs; Evangelos Christodoulou; James W Goding; Hideo Takakusa; Kazuya Kikuchi; Anastassis Perrakis; Tetsuo Nagano; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

Review 7.  A guide to murine coagulation factor structure, function, assays, and genetic alterations.

Authors:  J J Emeis; M Jirouskova; E-M Muchitsch; A S Shet; S S Smyth; G J Johnson
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

Review 8.  Thrombogenic and atherogenic activities of lysophosphatidic acid.

Authors:  Wolfgang Siess; Gabor Tigyi
Journal:  J Cell Biochem       Date:  2004-08-15       Impact factor: 4.429

9.  Role of LPA4/p2y9/GPR23 in negative regulation of cell motility.

Authors:  Zendra Lee; Ching-Ting Cheng; Helen Zhang; Mark A Subler; Jinhua Wu; Abir Mukherjee; Jolene J Windle; Ching-Kang Chen; Xianjun Fang
Journal:  Mol Biol Cell       Date:  2008-10-08       Impact factor: 4.138

Review 10.  Murine models of vascular thrombosis (Eitzman series).

Authors:  Randal J Westrick; Mary E Winn; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-28       Impact factor: 8.311

View more
  70 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

3.  Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells.

Authors:  Zachary Fulkerson; Tao Wu; Manjula Sunkara; Craig Vander Kooi; Andrew J Morris; Susan S Smyth
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

4.  Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis.

Authors:  Rihab Bouchareb; Marie-Chloé Boulanger; Lionel Tastet; Ghada Mkannez; Mohamed J Nsaibia; Fayez Hadji; Abdellaziz Dahou; Younes Messadeq; Benoit J Arsenault; Philippe Pibarot; Yohan Bossé; André Marette; Patrick Mathieu
Journal:  Eur Heart J       Date:  2019-05-01       Impact factor: 29.983

5.  Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.

Authors:  Adel Tabchy; Gabor Tigyi; Gordon B Mills
Journal:  Nat Struct Mol Biol       Date:  2011-02       Impact factor: 15.369

6.  Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Authors:  Sudeepti S Kuppa; Wei Jia; Shuying Liu; Ha Nguyen; Susan S Smyth; Gordon B Mills; Kevin K Dobbin; William J Hardman; Mandi M Murph
Journal:  Cancer Lett       Date:  2018-05-31       Impact factor: 8.679

7.  Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling.

Authors:  Hsin-Yuan Cheng; Anping Dong; Manikandan Panchatcharam; Paul Mueller; Fanmuyi Yang; Zhenyu Li; Gordon Mills; Jerold Chun; Andrew J Morris; Susan S Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-20       Impact factor: 8.311

8.  Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo.

Authors:  Jose L Tomsig; Ashley H Snyder; Evgeny V Berdyshev; Anastasia Skobeleva; Chifundo Mataya; Viswanathan Natarajan; David N Brindley; Kevin R Lynch
Journal:  Biochem J       Date:  2009-05-01       Impact factor: 3.857

Review 9.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

Review 10.  Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.

Authors:  N Panupinthu; H Y Lee; G B Mills
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.